Skip to main content

Rybrevant

Pronunciation: RYE–breh–vant
Generic name: amivantamab-vmjw
Dosage form: injection for intravenous infusion (350 mg/7 mL)
Drug class: Miscellaneous bispecific antibodies

Medically reviewed by Carmen Pope, BPharm. Last updated on Aug 28, 2025.

What is Rybrevant? NSCLC Cancer Treatment Overview

Rybrevant is used to treat non-small cell lung cancer (NSCLC) in adults with specific EGFR mutations. This bispecific antibody is used when lung cancer has locally advanced or metastasized. Rybrevant is given by IV infusion every 1 to 3 weeks.

Rybrevant (amivantamab) gained FDA approval on May 21, 2021, and is made by Janssen Biotech (Johnson & Johnson Innovative Medicine). There is no generic or biosimilar.

How Does Rybrevant Work for Lung Cancer?

Rybrevant is a targeted cancer therapy that works differently from traditional chemotherapy. It targets two specific proteins on cancer cells. 

Dual-Target Mechanism

Rybrevant FDA Approvals and Indications

First-Line Treatment (Newly Diagnosed)

Locally advanced or metastatic non-small cell lung cancer (NSCLC) with:

Second-Line Treatment (Disease Progression)

Locally advanced or metastatic non-small cell lung cancer (NSCLC) with:

Note: The safety and effectiveness of Rybrevant in pediatric patients has not been established.

Rybrevant Side Effects and Safety Profile

Common Side Effects (Combination with Lazertinib)

Common Side Effects (Combination with Carboplatin/Pemetrexed)

Common Side Effects When Used Alone

Serious side effects and warnings 

Rybrevant can cause the following serious side effects:

Infusion-related reactions. Infusion-related reactions are common but can be severe or serious and can include life-threatening (anaphylaxis) allergic reactions. Tell your healthcare provider right away if you get any of the following symptoms during your infusion of Rybrevant:

Lung problems. Rybrevant may cause lung problems that may lead to death. Symptoms may be similar to those symptoms from lung cancer. Tell your healthcare provider right away if you get any new or worsening lung symptoms, including shortness of breath, cough, or fever.

Blood clot problems. Blood clots are a serious, but common side effect of Rybrevant, when given together with another drug called lazertinib, may cause blood clots in the veins of your legs (deep vein thrombosis) or lungs (pulmonary embolism) that may lead to death. Your healthcare provider will start you on medicine to prevent blood clots for the first 4 months of treatment. Tell your healthcare provider right away if you have any signs and symptoms of blood clots, including swelling, pain, or tenderness in the leg, sudden unexplained chest pain, or shortness of breath.

Skin problems. Rybrevant can cause a severe rash, including blisters, peeling, skin pain and sores, redness, raised acne-like bumps, itching, and dry skin. You may use alcohol-free (such as isopropanol-free, ethanol-free) moisturizing cream to reduce the risk of skin problems. Tell your healthcare provider right away if you get any skin reactions. Your healthcare provider may treat you with medicines or send you to see a skin specialist (dermatologist) if you get skin reactions during treatment with Rybrevant.

Eye problems. Rybrevant may cause eye problems. Tell your healthcare provider right away if you get symptoms of eye problems, which may include:

Your healthcare provider may send you to see an eye specialist (ophthalmologist) if you get new or worsening eye problems during treatment with Rybrevant. You should not use contact lenses until your eye symptoms are checked by a healthcare provider.

Rybrevant may harm an unborn baby.

This is not a complete list of side effects, and others may occur. Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Before receiving this medicine

Before you receive Rybrevant, tell your healthcare provider about all of your medical conditions, including if you:

Pregnancy

Rybrevant can harm your unborn baby. Females who can become pregnant may need a pregnancy test to make sure they are not pregnant before treatment. Use birth control while using Rybrevant and for at least 3 months after your last dose. Tell your healthcare provider if you become pregnant or think you may be pregnant during treatment with Rybrevant.

Breastfeeding

It is not known if Rybrevant passes into your breast milk. Do not breastfeed during treatment and for 3 months after your last dose of Rybrevant.

How is Rybrevant administered?

Rybrevant will be given to you by your healthcare provider as an intravenous infusion into your vein.

You may be given pre-medication with an antihistamine, an antipyretic, and sometimes a glucocorticoid before each dose of Rybrevant to help reduce the risk of infusion-related reactions.

Rybrevant is often given in combination with other medicines, such as lazertinib, carboplatin, or pemetrexed.

Rybrevant is infused slowly to start with to reduce the risk of infusion-related reactions. Subsequent infusions will be quicker if you tolerate Rybrevant well.

If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment.

Dosing information

Dose of Rybrevant for NSCLC in combination with lazertinib or as a single agent

Less than 80 kg:

Greater than or equal to 80 kg:

Dose of Rybrevant for NSCLC in combination with carboplatin and pemetrexed

Less than 80 kg:

Greater than or equal to 80 kg:

Clinical Trial Results Supporting Rybrevant Efficacy

MARIPOSA Trial Results

MARIPOSA-2 Study Outcomes

PAPILLON Trial Data

CHRYSALIS Study Results

What happens if I miss a dose?

Call your doctor for instructions if you miss an appointment for your next injection.

What should I avoid while taking Rybrevant?

Rybrevant can cause skin reactions. You should limit your time in the sun during and for 2 months after your treatment. Wear protective clothing and use sunscreen during treatment. 

What other drugs will affect Rybrevant?

Other drugs may affect Rybrevant, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. No formal drug interaction studies have been conducted with Rybrevant.

Does Rybrevant interact with my other drugs?

Enter medications to view a detailed interaction report using our Drug Interaction Checker.

Rybrevant Package Insert 

Review the Rybrevant Package Insert for more detailed information about this medicine. Discuss any medical questions with your doctor or other health care provider. This is not all the information you need to know about this medicine for safe and effective use, and it does not take the place of talking to your doctor about your treatment.

Ingredients

Active ingredient: amivantamab-vmjw
Inactive ingredients: EDTA disodium salt dihydrate, L-histidine, L-histidine hydrochloride monohydrate, L-methionine, polysorbate 80, sucrose, and water for injection.

Available as a solution in a single-dose vial for intravenous infusion of 350 mg/7 mL (50 mg/mL).

Manufacturer

Rybrevant (amivantamab-vmjw) is made by Janssen Biotech, a pharmaceutical company owned by Johnson & Johnson.

Rybrevant Biosimilars

Biosimilar and interchangeable products are biological products that are highly similar to and have no clinically meaningful differences from the reference product.

Reference products

These are biological products that have already been approved by the FDA, against which biosimilar products are compared. There is 1 for Rybrevant.

Rybrevant (amivantamab-vmjw) - Janssen Biotech, Inc.
Formulation type Strength
Single-Dose Vial 350 mg/7 mL (50 mg/mL)

Popular FAQ

How do Exkivity and Rybrevant compare for NSCLC?

Exkivity has been withdrawn from the U.S. market. In clinical studies, close to 28% of patients had a partial response (tumor shrinkage) to Exkivity treatment for Exon 20 mutations and the response lasted for about 17.5 months. About 40% of participants had a response to single agent Rybrevant treatment, and the duration of response (DoR) lasted for a median of 11.5 months. Continue reading

How does Rybrevant work?

Rybrevant is a targeted medicine that works at the epidermal growth factor receptor (EGFR) gene mutation and MET receptor found in certain types of non-small cell lung cancer (NSCLC). EGFR and MET are proteins that help cells to grow. Targeting these proteins helps to slow down or stop cancer growth.

Continue reading
How is Rybrevant administered?

Rybrevant is given as an intravenous (IV) infusion into your vein. Your healthcare provider will administer this medication to you and determine your dose. It may be given alone, in combination with chemotherapy (carboplatin and pemetrexed), or with a kinase inhibitor called Lazcluze (lazertinib) for the treatment of EGFR mutated non-small cell lung cancer (NSCLC).

Continue reading

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.